Junshi Biosciences announces inclusion of toripalimab in the China National Reimbursement Drug List

Junshi Biosciences

29 December 2020 - Junshi Biosciences is pleased to announce that toripalimab has been included in the updated National Reimbursement Drug List (2020 Edition) for the treatment of melanoma by the China National Healthcare Security Administration. 

The primary drug format specification is the 80 mg/2 mL vial. 

Toripalimab is the only anti-PD-1 monoclonal antibody for the treatment of melanoma that has been included in the National Reimbursement Drug List.

Read Junshi Biosciences press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Market access , China